Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.74 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.69 |
| ▸ | FEN1 | P39748 | 10/20 | 0.63 |
| ▸ | ERCC5 | P28715 | 8/20 | 0.63 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.61 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154415 | 0.82 | EGLN1 (0.69) | KCNH2EGLN1FEN1ERCC5EGLN3 | |
| SCHEMBL2493881 | 0.82 | EGLN1 (0.65) | KCNH2EGLN1EGLN3EGLN2 | |
| SCHEMBL8244419 | 0.81 | EGLN1 (1.00) | EGLN1EGLN3EGLN2 | |
| SCHEMBL3777755 | 0.81 | EGLN1 (0.61) | KCNH2EGLN1EGLN3EGLN2 | |
| SCHEMBL2493231 | 0.80 | EGLN1 (1.00) | KCNH2EGLN1 | |
| SCHEMBL1960754 | 0.79 | EGLN1 (0.71) | KCNH2EGLN1EGLN3EGLN2 | |
| SCHEMBL8248294 | 0.79 | EGLN1 (0.77) | EGLN1EGLN3EGLN2 | |
| SCHEMBL8247149 | 0.79 | EGLN1 (0.73) | KCNH2EGLN1EGLN3EGLN2 | |
| SCHEMBL4158509 | 0.78 | FEN1 (0.67) | KCNH2FEN1ERCC5 | |
| SCHEMBL8244770 | 0.78 | EGLN1 (0.79) | EGLN1EGLN3EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | claimed |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| WO-2007136990-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176825-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN2, EGLN3 | KCNH2 3986/4885EGLN1 6/4885FEN1 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.